Andrew Tsai
Stock Analyst at Jefferies
(4.82)
# 482
Out of 5,090 analysts
167
Total ratings
55.4%
Success rate
24.6%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Initiated Coverage: Buy | $14 | $11.13 | +25.79% | 1 | Oct 29, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $20 | $8.48 | +135.85% | 3 | Oct 23, 2026 | |
| SLN Silence Therapeutics | Downgraded: Hold | $20 | $19.75 | +1.27% | 1 | Oct 19, 2026 | |
| BIIB Biogen | Reiterated: Buy | $255 | $253.62 | +0.54% | 11 | Oct 5, 2026 | |
| MRNA Moderna | Reiterated: Hold | $60 → $150 | $221.72 | -32.35% | 9 | Sep 22, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $42 → $50 | $16.69 | +199.58% | 6 | Sep 8, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $110 | $74.95 | +46.76% | 12 | Aug 31, 2026 | |
| NERV Minerva Neurosciences | Upgraded: Buy | $5 → $10 | $2.32 | +331.03% | 3 | Aug 14, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | $35 → $40 | $22.60 | +76.99% | 9 | Aug 13, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $65 | $36.33 | +78.92% | 6 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $380 | $144.43 | +163.10% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $550 | $285.93 | +92.35% | 8 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $11.57 | +55.57% | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $54.98 | +163.73% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $37.41 | +167.31% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $18.62 | +61.12% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.5 | $3.79 | +97.89% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.1683 | +434.76% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $26.29 | +14.11% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $7.58 | +322.16% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $4.05 | +146.91% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2.5 → $3 | $2.44 | n/a | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $0.85 | $1.42 | n/a | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.5 | $4.82 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $41.92 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $25.05 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $4.94 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $3.58 | n/a | 4 | Sep 16, 2024 |
Absci
Oct 29, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $11.13
Upside: +25.79%
Iovance Biotherapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $20
Current: $8.48
Upside: +135.85%
Silence Therapeutics
Oct 19, 2026
Downgraded: Hold
Price Target: $20
Current: $19.75
Upside: +1.27%
Biogen
Oct 5, 2026
Reiterated: Buy
Price Target: $255
Current: $253.62
Upside: +0.54%
Moderna
Sep 22, 2026
Reiterated: Hold
Price Target: $60 → $150
Current: $221.72
Upside: -32.35%
Dyne Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $50
Current: $16.69
Upside: +199.58%
BridgeBio Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $110
Current: $74.95
Upside: +46.76%
Minerva Neurosciences
Aug 14, 2026
Upgraded: Buy
Price Target: $5 → $10
Current: $2.32
Upside: +331.03%
Alto Neuroscience
Aug 13, 2026
Reiterated: Buy
Price Target: $35 → $40
Current: $22.60
Upside: +76.99%
Definium Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $65
Current: $36.33
Upside: +78.92%
Aug 11, 2026
Reiterated: Buy
Price Target: $380
Current: $144.43
Upside: +163.10%
Jun 30, 2026
Reiterated: Buy
Price Target: $550
Current: $285.93
Upside: +92.35%
May 14, 2026
Reiterated: Buy
Price Target: $18
Current: $11.57
Upside: +55.57%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $54.98
Upside: +163.73%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $37.41
Upside: +167.31%
Jan 12, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $18.62
Upside: +61.12%
Dec 31, 2025
Reiterated: Hold
Price Target: $7.5
Current: $3.79
Upside: +97.89%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.1683
Upside: +434.76%
Nov 24, 2025
Reiterated: Buy
Price Target: $30
Current: $26.29
Upside: +14.11%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $7.58
Upside: +322.16%
Nov 11, 2025
Reiterated: Buy
Price Target: $10
Current: $4.05
Upside: +146.91%
Aug 8, 2025
Reiterated: Hold
Price Target: $2.5 → $3
Current: $2.44
Upside: n/a
Aug 6, 2025
Reiterated: Hold
Price Target: $3 → $0.85
Current: $1.42
Upside: n/a
Mar 26, 2025
Reiterated: Buy
Price Target: $8.5
Current: $4.82
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $41.92
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $25.05
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $4.94
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $3.58
Upside: n/a